Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs

Sarah Gutkind, Laura E. Starbird, Sean M. Murphy, Paul A. Teixeira, Lauren K. Gooden, Tim Matheson, Daniel J. Feaster, Mamta K. Jain, Carmen L. Masson, David C. Perlman, Carlos Del Rio, Lisa R. Metsch, Bruce R. Schackman

Research output: Contribution to journalArticlepeer-review


Background: Using data from a randomized trial, we evaluated the cost of HCV care facilitation that supports moving along the continuum of care for HIV/HCV co-infected individuals with substance use disorder. Methods: Participants were HIV patients residing in the community, initially recruited from eight US hospital sites. They received HCV care facilitation (n = 51) or treatment as usual (n = 62) for up to six months. We used micro-costing methods to evaluate costs from the healthcare sector and patient perspectives in 2017 USD. We conducted sensitivity analyses varying care facilitator caseloads and examined offsetting savings using participant self-reported healthcare utilization. Results: The average site start-up cost was $6320 (site range: $4320-$7000), primarily consisting of training. The mean weekly cost per participant was $20 (site range: $4-$30) for care facilitation visits and contacts, $360 (site range: $130- $700) for supervision and client outreach, and $70 (site range: $20-$180) for overhead. In sensitivity analyses applying a weekly caseload of 10 participants per care facilitator (versus 1–6 observed in the trial), the total mean weekly care facilitation cost from the healthcare sector perspective decreased to $110. Weekly participant time and travel costs averaged $7. There were no significant differences in other healthcare service costs between participants in the intervention and control arms. Conclusion: Weekly HCV care facilitation costs were approximately $450 per participant, but approximately $110 at a real-world setting maximum caseload of 10 participants per week. No healthcare cost offsets were identified during the trial period, although future savings might result from successful HCV treatment.

Original languageEnglish (US)
Article number109265
JournalDrug and Alcohol Dependence
StatePublished - Mar 1 2022
Externally publishedYes


  • Care facilitation
  • Cost
  • HIV
  • Hepatitis C
  • Substance use disorder

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs'. Together they form a unique fingerprint.

Cite this